Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pola-ZR2 for newly diagnosed elderly diffuse large B-cell lymphoma
ChiCTR2400092588Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of polatuzumab vedotin, zanubrutinib, lenalidomide and rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Primary endpoint: Complete response rate at the end of induction treatment. Started Jul 2024; status: recruiting.
02
Drugs
polatuzumab vedotinzanubrutiniblenalidomiderituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2400092588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092588.